BioSpace News Archive

Drug Development

ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors

Potential for new immune-oncology therapy using an antibody drug conjugate that targets regulatory T cells

January 7, 2019
·
4 min read
Policy

Eisai’s New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration

For Adjunctive Treatment of Partial Onset Seizures

January 7, 2019
·
5 min read
Biotech Beach

Roswell Biotechnologies Secures $32 Million Series A Financing Round

Harnessing the Power of Molecular Electronics to Revolutionize DNA Sequencing

January 7, 2019
·
2 min read
Drug Development

A New Day, a New Vant. Roivant Launches Alyvant Ahead of J.P. Morgan 2019

Biotech entrepreneur Vivek Ramaswamy has launched another subsidiary for Roivant Sciences. Ramaswamy will provide an update on the new company, as well as other members of the Roivant family during a Monday presentation at JPM19.

January 7, 2019
·
3 min read
·
Alex Keown
Business

Sanofi and Regeneron Restructure Immuno-Oncology Collaboration to Add Two New Products

Tarrytown, NY-based Regeneron Pharmaceuticals and Paris-based Sanofi restructured a 2015 agreement to develop immuno-oncology (I/O) treatments. That deal was scheduled to wrap in 2020, but the revision adds two clinical-stage bispecific antibodies to the collaboration.

January 7, 2019
·
2 min read
·
Mark Terry
Deals

BioSpace’s List of January 2019 Life Science IPOs

A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.

January 7, 2019
·
1 min read
·
Editorial Staff
Drug Development

Galapagos starts first Phase 1 trial with Toledo compound

Novel target class with dual action in inflammatory disorders

January 7, 2019
·
4 min read
Business

Adaptive Biotechnologies and Genentech Launch Personalized Cancer-Care Program Worth $2 Billion+

Seattle-based Adaptive Biotechnologies forged a collaboration with Genentech that could be worth up to $2 billion to develop and commercialize novel neoantigen directed T-cell therapies for the individualized treatment of a broad range of cancers.

January 7, 2019
·
3 min read
·
Alex Keown
Business

Gilead Inks $785 Million Deal With Yuhan for NASH Development

Gilead Sciences is acquiring the global rights to develop and commercialize novel small molecules against two targets from Yuhan Corporation, based in South Korea. They drugs will be developed to treat advanced fibrosis related to nonalcoholic steatohepatitis (NASH).

January 7, 2019
·
3 min read
·
Mark Terry
Business

Executive Women In Bio Releases First Annual Directory of Boardroom Ready Executive Profiles

Applications for the 2019 Boardroom Ready program now open

January 7, 2019
·
3 min read